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1. Introduction
More than 200 years have passed since the well- An essay on the shaking palsy
English surgeon James Parkinson first described the clinical features of (J. Obeso 
et al., 2017). Nonetheless, although important advances have been achieved in the understanding and 
therapy of PD, there is still no cure available. PD affects millions of people worldwide, thus being the 
second most common neurodegenerative disease, preceded on (de Lau & Breteler, 
2006). These numbers indicate that PD represents a tremendous burden not only for the individual patients 
and their caregivers, but also for the society and health system (Findley et al., 2003; Spottke et al., 2005).
Moreover, due to the aging of modern populations, the number of PD patients is projected to increase in 
the next future (Dorsey et al., 2007).  It is thus clear that further research is needed to gain a better insight 
into the causal factors of PD and possibly to implement novel and more effective therapeutic options.   
1.1. Clinical and neuropathological features of isease
PD was first conceptualized as a motor disease whose core clinical features are bradykinesia (or akinesia), 
tremor at rest, rigidity and postural instability (Jankovic, 2008). Other frequent motor impairments are 
freezing of gait and a bent-forward posture. Additionally, a multitude of non-motor symptoms has been 
nowadays associated with PD through the disease course (Chaudhuri, Healy, & Schapira, 2006; Schapira, 
Chaudhuri, & Jenner, 2017). For example, it is well established that both gastrointestinal symptoms (e.g. 
constipation) and olfactory deficits could precede the clinical onset of the motor symptoms by several years. 
Other non-motor symptoms are rapid eye movement REM sleep behavior disorder, neuropsychiatric 
manifestations, such as psychosis and visual hallucination, and even cognitive deficits. As for this latter, 
minor cognitive deficits could be present since the onset of PD, defining the so-called mild cognitive 
impairment (MCI) condition (Aarsland et al., 2010). Specific clinical diagnostic criteria for MCI due to PD 
have been recently published (Litvan et al., 2012). It is estimated that MCI in PD affects about one-third of 
newly diagnosed PD patients (Santangelo et al., 2015). MCI in PD is of particular interest because it is 
2
often prodromal of a clear full-blown dementia that might eventually emerge during the disease course 
(Pigott et al., 2015). This clinical picture takes the name of PD-dementia and poses a further burden for the 
affected patients (Lawson et al., 2016) disease,
but it can be better described as a multisystem disease, including both motor and non-motor symptoms 
(Lang & Obeso, 2004). Notably, this clinical complexity is reflected at the neuropathological level. 
The hallmark of PD is the degeneration of dopaminergic neurons in the substantia nigra pars compacta in 
the midbrain. Here, alpha-synuclein aggregates are the principal components of Lewy bodies that are the 
main histopathological finding in PD, though their exact origin is still unknown (Spillantini et al., 1997).
The substantia nigra is a tiny brain region (approximately. 5 mm thick) that sends axonal projections to the 
dorsal striatum, playing a crucial role in movement planning and execution. In the presence of PD, the 
nigro-striatal dopaminergic pathway is severely affected, resulting in overt motor deficits. Of note, clinical 
manifestations of PD typically emerge when already a considerable portion of dopaminergic neurons in the 
substantia nigra have been lost, with estimates ranging from 30 to 70% (Cheng, Ulane, & Burke, 2010).
Other main hotspots for the very early neurodegeneration in PD are in non-catecholaminergic neurons, such 
as in the olfactory bulb and in the dorsal glossopharyngeus-vagus complex, where alpha-synuclein 
aggregates have been detected even in the preclinical stages (Del Tredici et al., 2002). Recent studies on 
animal models of PD suggested that the alpha-synuclein aggregates originate initially from the 
gastrointestinal tract and are subsequently retrogradely transferred to the brain through the vagal nerve. 
Indeed, it has been shown in several animal models of PD that alpha-synuclein can travel bi-directionally 
along the vagus nerve, thus strengthening the hypothesis of long-distance spreading of pathological protein 
aggregates (Dehay, Vila, Bezard, Brundin, & Kordower, 2016). The first validation of this hypothesis in 
humans has been advanced by Knudsen et al. (2018) who studied 22 patients affected by idiopathic REM-
sleep behavior disorder, a condition known to be prodromal to PD and Lewy bodies dementia, and 
compared them to PD patients and healthy controls. The study implemented positron emission tomography 
(PET) with multiple tracers in combination with multimodal magnetic resonance imaging (MRI), showing 
3
impairment in both sympathetic and parasympathetic peripheral nervous systems, as well as in the locus 
coeruleus in both prodromal and full-blown PD cases. However, consistent with the proposed hypothesis, 
most of the prodromal PD cases did not show evidence for central nervous system deficit (i.e. they had 
normal dopaminergic levels in the putamen) (Knudsen et al., 2018). According to these findings, PD 
pathology starts in the peripheral autonomic nervous system and it is later transferred to the spinal cord, the 
brainstem and only finally to the central nervous system. Nevertheless, this model needs further validation 
and might be applicable only to a subgroup of the total idiopathic PD cases, who clinically present with 
early REM-sleep behavior disorder and gastrointestinal problems (Knudsen et al., 2018; Lionnet et al., 
2018). As PD progresses in the central nervous system, alpha-synuclein aggregates are found in many other 
brain regions besides the substantia nigra, olfactory bulb and basal ganglia. Braak and Braak (2003) 
analyzed over one hundred post-mortem brain specimen from PD patients and identified a specific pattern 
for the spreading of alpha-synuclein in the brain (Braak et al., 2003). Interestingly, as for other 
neurodegenerative diseases, it has been proposed that PD pathology spreads through the brain following 
specific neural pathways that are present in the healthy brain. In the next section, I will introduce the 
possible link between PD and brain connectivity architecture.
Figure 1. Spreading of intracellular PD pathology in the brain.
Network-like spreading of PD-related pathology in the central nervous system starts from the brainstem 
(IX/X dorsal motor nucleus) or from the olfactory bulb. It then extends to the anteromedial temporal cortex 
and later on to the associative sensory cortex, to the prefrontal cortex and, only in the later stages, to the 
primary sensorimotor cortex. Different color shades represent the spatial progression of PD pathology over 
time. Figure adapted from Braak et al., 2003, Neurobiology of aging, 24(2), 197-211.
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1.2. disease 
The brain is organized in highly complex networks, whose properties can be studied at different levels. Two 
useful concepts to investigate the brain structure and function are structural and functional connectivity. 
The former refers to anatomical links between neurons or defined brain structures. It can be studied at the 
level of single neuron-to-neuron connections up to the definition of large-scale cortical networks (Sporns, 
Chialvo, Kaiser, & Hilgetag, 2004). The latter instead, takes into account the deviations from statistical 
independence (e.g. correlation or covariance) over time between different neural units (Sporns et al., 2004).
A recent and particularly interesting topic is the application of graph theory to the study of functional 
connectivity in the brain (Bullmore & Sporns, 2009). Notably, the interrelation between structural and 
functional networks is one of the hot topics in current neuroscience research. In this context, one of the 
most credited hypotheses is that structural networks pose a constraint to the functional brain organization 
(Honey, Kötter, Breakspear, & Sporns, 2007).
The knowledge about brain structural and functional networks has contributed to formulating hypotheses
for conceptualizing several neurodegenerative diseases including PD. Within this framework, the study of 
brain connectivity at multiple levels plays a crucial role to identify and test models of the spreading of PD-
related pathology in the brain. As anticipated in the previous section, at the molecular/cellular level, a prion-
like mechanism of alpha-synuclein spreading in the brain has been proposed (Brettschneider, Tredici, Lee, 
& Trojanowski, 2015). According to this hypothesis, alpha-synuclein spreads across the brain by means of 
cell-to-cell transmission. Significant findings have been reported in support of this hypothesis, thus 
emphasizing how neural networks contribute to increasing the vulnerability of selected neurons. Based on 
similar concepts, the in vivo study of brain functional connectivity by means of resting-state functional MRI
has led to the so-called molecular nexopathy hypothesis for understanding neurodegenerative diseases 
(Warren, Rohrer, & Hardy, 2012; Warren et al., 2013). According to this hypothesis, neurodegenerative 
diseases, including PD, can be conceptualized as brain disconnection syndromes generated by the 
conjunction of intrinsic brain network characteristics and molecular pathology. The study of brain 
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functional connectivity in PD has been gaining more and more space. It is now considered as a useful tool 
in order to understand how PD affects the brain. Here, variations in brain connectivity patterns can serve 
as a potential biomarker for the disease.
1.3. The need for in vivo biomarkers  
In general terms, a biomarker is an objective indication of the medical state of a patient that can be measured 
accurately and reproducibly (Strimbu & Tavel, 2010). In the context of this thesis, I will focus on 
neuroimaging biomarkers for PD, in particular on those based on MRI. Given this broad definition, it is 
clear that the search for biomarkers specifically related to PD might have at least three main rationales: 1. 
To provide an early and accurate diagnosis of the disease; 2. To monitor the effects of existing and, 
potentially, new treatment options; 3. To predict specific clinical features of the patients or their most likely 
disease prognosis, as well as the outcome of therapeutic interventions.
The first point has been under scrutiny for several years and periodically leads to the formulation of revised 
clinical and research diagnostic criteria for neurodegenerative diseases. The aim is to reach the highest 
possible accuracy in differentiating patients with PD from both healthy controls and other
neurodegenerative diseases (e.g. atypical parkinsonian syndromes). In this context, the study of in vivo
brain imaging has played a major role in the last two decades (Saeed et al., 2017). For example, the 
investigation of striatal presynaptic dopamine function by means of molecular PET imaging reliably and 
consistently identifies dopamine loss in PD (Kaasinen & Vahlberg, 2017). Indeed,  up to now, the only 
brain biomarker mentioned in the most recently published PD diagnostic criteria is the normal presynaptic 
dopaminergic function detected by molecular imaging, a finding that excludes the presence of PD (Postuma 
et al., 2015). Despite the fact that several other neuroimaging techniques have been already investigated, 
no other biomarkers have been integrated into the official diagnostic workup for PD. This represents a
biomarkers have been integrated in the most recent criteria (Dubois et al., 2014). Another seemingly useful 
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biomarker for PD might be the study of the substantia nigra using MRI (Lehéricy, Sharman, Santos, Paquin, 
& Gallea, 2012). In particular, the imaging of the substantia nigra and its projections as studied with
diffusion MRI can differentiate patients and controls with an accuracy of 100% (Vaillancourt et al., 2009)
and is under consideration for further inclusion as supportive diagnostic feature (Cochrane & Ebmeier, 
2013). On the other hand, many studies implemented structural MRI to identify the patterns of 
morphological changes related to PD, but the results have been so far highly heterogeneous (Saeed et al., 
2017). This heterogeneity may originate from several confounding factors (e.g. different clinical features 
of the studied PD cohorts and different methodologies applied in the analyses), but might also reflect a lack 
of specificity of MRI for PD detection. In addition, several MRI studies focused on the study of resting-
state functional connectivity, providing heterogeneous but encouraging results, as summarized in a recent 
meta-analysis (Tahmasian et al., 2017). As aforementioned, the PD clinical symptoms clearly emerge when 
many of the nigro-striatal projections are already damaged. It is thus clear that biomarker research should 
focus not only on brain changes at the moment of the diagnosis, but especially on preclinical stages. This 
led to an entirely new line of research that specifically investigated clinical and neuroimaging findings that 
might antedate the emergence of a clear PD clinical picture (Becker et al., 2002). Of particular interest is 
the study of carriers of genetic variants that increase the risk of developing PD.       
The second research interest where biomarkers can play a crucial role is the optimization and understanding 
of existing treatment options and development of new ones. In this respect, the study of brain structure and 
function using MRI could play a crucial role. For example, several studies have investigated functional 
connectivity changes in the brain induced by levodopa, the most common and effective symptomatic 
treatment for PD to date (Tahmasian et al., 2015). Indeed, despite this pharmacological therapy of PD 
provides hitherto the best available treatment for motor symptoms, its exact effect on the brain is still not 
completely understood (Fahn, 2005; Parkinson Study Group, 2004; Olanow, 2015). Resting-state functional 
MRI studies have shown that large-scale brain functional networks are modulated by levodopa intake both 
in healthy subjects (Kelly et al., 2009) and in patients with PD (Tahmasian et al., 2015). Moreover, the 
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availability of accurate imaging biomarkers for PD might be a useful tool to monitor the impact of new 
treatments on brain function and its pathological changes. Following this idea, a great interest has been 
recently addressed to the creation of a new radiotracer for alpha-synuclein that could represent an invaluable 
tool not only for the early identification of PD, but also for monitoring the efficacy of new disease-
modifying treatments (Eberling, Dave, & Frasier, 2013).
The third possible implementation of neuroimaging biomarkers for PD is at the prediction level. This is 
probably the most exciting and promising challenge in the current biomarker research (Shaw, Korecka, 
Clark, Lee, & Trojanowski, 2007; Woo, Chang, Lindquist, & Wager, 2017). One aspect of the prediction 
was already introduced and refers to the early identification of PD. Here the goal would be to identify PD 
markers at different levels (e.g. in the brain, but also clinical signs and serum/cerebrospinal fluids markers) 
before the clinically evident emergence of the core motor symptoms (Becker et al., 2002). Again, 
el. It has been indeed demonstrated, by 
means of amyloid and glucose PET and MRI, that pathological and morphological changes can precede the 
(Jack Jr et al., 2013). Specifically, this was achieved studying 
PRES1 and PRES2) (Bateman et al., 2012), as well as on carriers of the apolipoprotein E (APOE) 4 alleles 
that increase the risk of A and on individuals with a known family history for the disease 
(Mosconi et al., 2007; Mosconi et al., 2010). Up to date, few genetic mutations have been also associated 
with autosomal dominant and autosomal recessive PD inheritance as well as with increased risk in sporadic 
PD, thus opening a new window on preclinical stages (Becker et al., 2002; Farrer, 2006). The two most 
common genes linked to autosomal dominant PD are indeed the Leucine-rich repeat kinase 2 (LRRK2) and 
the synuclein alpha (SNCA), while mutations in parkin and phosphatase and tensin homolog on 
chromosome 10 (PTEN)-induced kinase 1(PINK1) are associated with recessive inheritance (Farrer, 2006; 
Lesage, Brice, & disorders, 2012; Nuytemans, Theuns, Cruts, & Van Broeckhoven, 2010). Focusing on 
carriers of these genetic risk factors might thus shed light on the very beginning of PD well before clinical 
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onset. For example, genetic screening is one focus of the recent Parkinson Progression Marker Initiative 
(PPMI; ), a large multicenter research effort that aims to uncover novel PD biomarkers.  However, genetic 
mutations account for only about 10% of total PD cases, thus posing a limit to the generalizability of such 
findings.
Another important aspect of this research line concerning predictive models would be the prediction of 
clinical progression in individual patients. For example, as abovementioned, about one-third of PD patients 
present with mild cognitive impairment (MCI) since the early stages of the disease, which is per se a risk 
factor for the progression to PD with dementia (Pigott et al., 2015). Combining this clinical information 
with neuroimaging evidence could increase the precision in identifying the subjects that are at major risk 
to convert to dementia from those who will be stable or even revert to normal cognition. Some MRI studies 
have indeed already provided preliminary but encouraging results in this respect. Abós et al. (2017) 
combined the study of brain functional connectivity and machine learning approaches and were able to 
classify PD patients with MCI from those without MCI with an 80% accuracy (Abós et al., 2017). Indeed, 
combining clinical data and in vivo biomarkers could provide great help in tailoring treatment approaches
and planning the most appropriate care for each patient. 
Tightly related to this latter point is another possible application of predictive models in PD, which is the 
identification of the best treatment option at single-subject level. Up to date, the dopamine precursor 
levodopa (L-3,4-dihydroxyphenylalanine) and dopamine agonists have been the preeminent 
pharmacological treatment for PD (LeWitt, 2008). However, although they have helped to relieve PD 
symptoms in millions of affected patients, they provide only a symptomatic treatment and they are 
ineffective in slowing down the underlying neurodegenerative processes. In addition, the efficacy of 
dopaminergic treatment decreases over time and frequently leads to severe motor and non-motor side 
effects, such as dyskinesia, off freezing and visual hallucinations (J. A. Obeso, Olanow, & Nutt, 2000).
Predictive models based on neuroimaging data could help in identifying those subjects who are more prone 
to show such treatment-related complications, providing the clinician with a new perspective when planning 
long-term treatment of PD patients. Another more recent treatment option for PD is deep brain stimulation 
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(DBS) that was first introduced to overcome the severe side effects of chronic pharmacological treatment
(Benabid, Chabardes, Mitrofanis, & Pollak, 2009). In DBS, micro-electrodes are inserted during a surgical 
pro
pars interna that show abnormally increased neuronal activity in PD patients. The electrodes send high-
frequency electric impulses to these brain regions rebalancing neural transmission within the distributed 
network and significantly improving motor symptoms (De Hemptinne et al., 2015). Since benefits of DBS 
are mediated by connectivity between the stimulation site and other distributed brain regions, Horn et al. 
(2017) were able to define, using machine learning, which functional and structural brain connectivity 
patterns are predictive of a beneficial clinical outcome in PD (Horn et al., 2017). Specifically, with the 
electrodes implanted in the subthalamic nucleus, they showed that the structural connectivity with the
supplementary motor area and the inverse functional connectivity with primary motor cortex were the best 
predictors of clinical outcome. This knowledge might help in treating individual PD patients, for example 
by assessing if the response is appropriate to electrode placement.
Overall, identifying new PD biomarkers stands out as one of the crucial challenges on the way to a better 
understanding and treatment of PD. In particular, the implementation of biomarkers for both early diagnosis 
and prediction of disease and treatment progression is much needed to foster the current clinical and 
research approaches to PD.  
1.4. Magnetic Resonance Imaging
MRI allows investigating different brain properties in vivo and non-invasively, thus being the method of 
choice for studying brain mechanisms in both research and clinical settings. MRI studies in PD patients 
exponentially increased over the past years (Figure 1) and today represent one of the most active branches 
in PD research. This picture is impressive when thinking that the very first image of a full human body with 
MRI was acquired as little as four decades ago, namely in 1977 by Raymond Damadian (Damadian,
Goldsmith, & Minkoff, 1977). In the previous sections, some concepts about brain structural and functional 
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architecture have been introduced. In the following, the MRI methodologies used for the in vivo study of 
these features are described.
Figure 2.
The plot displays the rising number of publications in peer-reviewed journals over the past 20 years (1998 
Science Core Collection databases on the 04.01.2019. 2861 publications were found that were overall cited 
64,088 times. 
1.4.1. Structural Imaging
MRI is based on the application of a strong and stable magnetic field to the human body. This causes the 
protons in water nuclei to align their spins with the externally applied magnetic field. A specific 
radiofrequency is then applied, leading to energy exchange and change in orientation of the protons in the 
imaged tissue. After the radiofrequency pulse, the protons release back the gained energy from the 
radiofrequency and return to their original position (relaxation). In this phase, H+ ions emit a radio signal 
in the same frequency of the received pulse (nuclear magnetic resonance) and proportional to the strength 
of the magnetic field. During the relaxation phase, different contrasts can be measured, namely T1 and T2, 
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by varying the repetition time (TR, i.e. time between successive pulses) and the echo time (TE, i.e. time 
between the pulse and the receipt of the echo signal). T1 is the recovery of magnetization along the 
longitudinal axis of the magnetic field, while T2 is the decay of magnetization along the transverse axis. 
Notably, each tissue compartment (e.g. in the brain, grey matter, white matter, cerebrospinal fluid) has a 
unique T1 and T2, thus making it possible to differentiate them and create images with different color
contrasts. In T1-weighted images, a long T1 (e.g. in water), leads to darker images, while a short T1 (e.g. 
in fat) leads to bright images. Thus, cerebrospinal fluid will appear in black contrast, grey matter as grey
and white matter as bright white. These images are ideal for investigating morphological changes in the 
brain. On the contrary, in T2-weighted images, water has a longer T2 time as compared to fat, since it is 
less efficient in the exchange of energy, thus cerebrospinal fluid will appear whiter than grey matter that is,
in turn, brighter than white matter. T2-weighted images are commonly implemented in the clinical work-
up to identify bleedings in the brain or white-matter lesions. In the papers presented in this thesis, T1-
weighted MRI has been used to investigate volume changes in the brain of PD patients. Structural MRI is 
extremely useful for both clinical and research purposes, as it provides static pictures of the brain in a 
precise moment. Moreover, the research has gone further to capture the dynamic functioning of the brain 
by means of functional neuroimaging.   
1.4.2. Resting-state functional imaging
The transition from structural to functional MRI is often compared to the one from photography to movies. 
Following this analogy with the visual arts, MRI became a tool to image the brain dynamics by combining
several frames of the brain collected over a certain time-span. Functional MRI captures the hemodynamic 
response in the brain, capitalizing on the association between neuronal activity and blood flow (Raichle, 
1998). Specifically, functional MRI is based on T2* relaxation time, i.e. the effective T2 influenced by 
inhomogeneities in the magnetic field, and on blood-oxygen level dependent (BOLD) imaging. In brief, 
when a set of neurons is active, it requires oxygen, which is supplied through the bloodstream. This leads 
to changes in the ratio between the concentration of oxyhemoglobine (diamagnetic) and deoxyhemoglobine 
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(paramagnetic) in blood vessels surrounding the active brain site. Namely, when a brain region is more 
active, a signal increase is detected (due to the increased presence of oxyhemoglobin) as compared to the 
inactive state. Logothetis et al. combined functional MRI and the recording of local field potentials in 
monkeys and demonstrated that changes in the BOLD signal are coupled with input and intra-processing 
of the studied brain areas (Logothetis, Pauls, Augath, Trinath, & Oeltermann, 2001). Functional MRI has 
represented a huge step forward in neuroimaging, allowing in vivo the study of brain activity associated 
with many cognitive and behavioral tasks. 
A more recent advance of this technique is resting-state functional MRI. This technique allows the study of 
brain dynamics during a task-free condition. Resting-state functional MRI focuses on spontaneous 
fluctuations in BOLD activity that are not induced by external stimuli. Indeed, the brain is active even in 
the absence of external stimulation and its dynamics at rest are reliably reproducible, giving rise to the
entirely new field of research focused on functional connectivity (Deco, Jirsa, & McIntosh, 2011). The 
organization into dynamic functional networks is now recognized as an intrinsic property of the brain (Fox 
et al., 2005). As previously introduced, the study of brain functional connectivity using resting-state 
functional MRI is on the forefront in MRI research in neurodegenerative diseases (Seeley, Crawford, Zhou, 
Miller, & Greicius, 2009) and seems to be a promising biomarker for the characterization of PD (Tahmasian
et al., 2015; Tahmasian et al., 2017).
2. Research projects and hypotheses
Heterogeneity among PD patients has been described in both response to pharmacological treatment 
(Constantinescu, Richard, & Kurlan, 2007) and in clinical presentation (Schapira et al., 2017; Thenganatt 
& Jankovic, 2014).  This doctoral project, combining multimodal MRI and clinical data, aims to uncover 
the neural sources of this variability, thus revolving around two main aspects of PD research: dopaminergic 
treatment and cognitive deficits. 
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As for the dopaminergic treatment, Project I investigated the differences in brain resting-state functional 
connectivity in PD patients chronically treated with dopaminergic therapy during the medicated (ON) and 
the unmedicated (OFF) states. Here we hypothesized to find selective brain changes in resting-state 
functional connectivity that could be useful to understand how brain networks are re-modulated by PD 
pharmacological therapy and, potentially, as biomarkers to monitor treatment outcome. Moreover, in 
Project II, we applied machine learning techniques to predict treatment outcome based on both 
predictive model to identify which features define the patients who better respond to pharmacological 
treatment. 
Project III focused on the study of both structural and resting-state  functional MRI for the identification of 
the neural signature of MCI due to PD. This topic is of utmost interest, since cognitive impairment affects 
at least one-third of PD patients (Litvan et al., 2011), further degrading their life quality and often leading 
to overt dementia (Hoogland et al., 2017). Specifically, we expected changes in brain networks supporting 
cognitive and associative processes, such as the default mode network, the attention networks and the 
executive one. Gaining a better understanding of the brain abnormalities underpinning cognitive 
impairment in PD might be useful not only as an additional biomarker for this condition, but also to inform 
novel treatment strategies. 
In addition, with Project IV we aimed to revise and quantitatively summarize the recent literature on PD 
diagnostic imaging biomarkers. Specifically, we run a meta-analysis of whole-brain structural MRI and 
[18F]-fluorodeoxyglucose-PET (FDG-PET) studies that compared PD patients and healthy controls. Indeed, 
this line of research provided heterogeneous and often contradictory results, thus making it crucial to 
quantitatively review the literature to provide an objective picture. Previous meta-analytical studies 
provided relevant information both concerning PD (e.g. studying dopaminergic PET imaging (Kaasinen & 
Vahlberg, 2017)) and in other neurodegenerative diseases (Schroeter & Neumann, 2011; Schroeter, Raczka, 
Neumann, & Von Cramon, 2008; Schroeter, Stein, Maslowski, & Neumann, 2009), including parkinsonian 
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syndromes (Albrecht, Bisenius, Neumann, Whitwell, & Schroeter, 2019; Albrecht, Bisenius, Schaack, 
Neumann, & Schroeter, 2017). In line with the aim of Project III, we also performed a meta-analysis 
specifically focusing on MRI and FDG-PET signatures of PD with cognitive deficits. 
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The presented research projects are an example of how the combination of multimodal MRI imaging and 
advanced analytical methods can advance the understanding of clinical and treatment-related brain changes 
in PD and foster the development of novel neuroimaging biomarkers. In the following, the main findings 
and their potential implications are discussed. 
Project I dealt with the understanding of how dopaminergic therapy modifies the brain functional 
connectivity. It emerged that chronic dopaminergic therapy has a strong impact on brain interconnectedness 
at rest, targeting both motor and non-motor regions. This finding supports the implementation of resting-
state functional MRI as an objective marker of treatment response, in line with the recent literature in both 
PD and other parkinsonian syndromes (Eckert & Eidelberg, 2005; Matthews, Honey, & Bullmore, 2006; 
Tahmasian et al., 2015). Proper quantification of treatment effects on the brain will be essential for future 
clinical trials testing new therapeutic options for neurodegenerative diseases. Brain imaging biomarkers 
could indeed provide a clear assessment of treatment effectiveness a desideratum, especially in the case 
of disease-modifying therapies (Chen-Plotkin et al., 2018) and could also be implemented as safety 
markers to shed light on potentially covert side effects (Hampel et al., 2010). In addition, the 
implementation of longitudinal study designs, following patients since the very beginning of PD, as well as 
of larger samples will provide a more detailed description of how neuroimaging biomarkers change over 
time in response to both treatment and clinical progression. To this aim, the creation of consortia and 
multicenter initiatives to collect and share clinical data represents a big step forward. Such enterprises, such 
(Marek et al., 2011)
Disease Neuroimaging Initiative (ADNI) (Petersen et al., 2010) are successful examples.
As for Project I, also Project II focused on MRI-based biomarkers in relationship to dopaminergic treatment 
for PD. In summary, we showed how it is possible to combine clinical information and MRI structural data 
to predict the response to pharmacological treatment. Indeed, older age and a more severe brain structural 
impairment in PD patients independently predict poorer treatment response. This latter finding highlights 
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two main points that are common in the up-to-date biomarkers research: i) the potential of MRI-based 
markers in clinical trials and ii) the emerging role of predictive models in clinical research.
The advantage of including neuroimaging-based biomarkers in clinical trials is clear. For example, they can 
be used to select the patients and stratify them according to their baseline characteristics or their likelihood 
to benefit from a specific treatment option. This use of neuroimaging biomarkers has been already
implemented in past and current clinical trials for neurodegenerative disease. For example, in the study of 
Aducanumab (BIIB037) amyloid positivity from PET
imaging was chosen as a mandatory inclusion criterion and MRI is used to quantify treatment-related 
changes in amyloid-related imaging abnormalities (https://clinicaltrials.gov/ct2/show/NCT03639987). On 
the same line, in vivo molecular imaging of the dopaminergic system has served as primary or secondary 
endpoint in clinical trials for PD comparing either levodopa and dopamine agonists or the impact of early 
versus late levodopa administration on PD progression (Politis, 2014). More recently, also network imaging 
biomarkers specific for PD have been identified and implemented in clinical trials to objectively quantify 
treatment response (Schindlbeck & Eidelberg, 2018). Hence, supporting further discovery of effective 
neuroimaging biomarkers to diagnose neurodegenerative diseases and predict/monitor their progression is
imperative for the years to come. This aim will likely benefit from the improvement of neuroimaging 
techniques, such as hybrid PET/MRI systems (Barthel, Schroeter, Hoffmann, & Sabri, 2015), and from 
fusion of multiple brain imaging data sources (Calhoun & Sui, 2016).
Project II emphasizes also the relevance of predictive models in clinical research. Machine learning 
techniques represent a powerful analytical tool to tackle several clinical issues (Obermeyer & Emanuel, 
2016). The main idea behind machine learning is that an algorithm can automatically learn from sample
data to perform tasks such as image-based diagnosis, identification of subjects at risk for a specific medical 
condition or, as in the aim of Project II, prediction of treatment response. These methods have been 
effectively implemented in several medical applications (De Fauw et al., 2018; Esteva et al., 2017) and 
have been recently applied also on neuroimaging data for the study of neurodegenerative diseases as
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reviewed by Woo et al. (Woo et al., 2017). Concerning the treatment of neurodegenerative disease, 
machine-learning algorithms could help to decide the best treatment strategy for each patient and to 
optimize the treatment itself. For example, in the case of deep brain stimulation for PD, machine learning
can predict structural and functional connectivity profiles from the electrode site that are associated with 
the best clinical outcome for the patient (Horn et al., 2017). Further improvements in this direction are 
likely to transform the management of PD (Miljkovic et al., 2016; Shamir, Dolber, Noecker, Walter, & 
McIntyre, 2015). Note, that large sample sizes are important for creating reliable and reproducible 
predictive models based on machine learning. After small projects, like the one reported in this thesis, 
explored the feasibility and the relevance of neuroimaging-based biomarkers, the must for the future is to 
move further (Woo et 
al., 2017).     
This thesis touched on another crucial issue in PD research: clinical heterogeneity. We recognize that PD 
is a multifaceted syndrome, much more complex than the core motor deficits (Schapira et al., 2017).  Project 
III analyzed the differences between PD patients with and without MCI, combining detailed 
neuropsychological testing and MRI data. We found that functional brain network changes in the parieto-
frontal attention network constitute a specific signature for MCI due to PD, thus providing a clearer
understanding of the neural underpinnings of cognitive deficits in PD. Longitudinal studies have shown 
that similar biomarkers can predict which PD patients are at higher risk to develop PD dementia in later 
disease stages (Mak et al., 2015). The availability of such information is relevant for timely planning of
management and of treatment for these patients. Furthermore, the stratification of patients in clinical trials 
according to their baseline characteristics represents a clear advantage. The search for such diagnostic 
imaging biomarkers was the central research question of Project IV.
Project IV applied meta-analytical algorithms to summarize the findings from previous literature in search 
for specific PD diagnostic imaging biomarkers based on T1-weighted MRI imaging and FDG-PET. Meta-
analytical methods are valuable tools in current research, since they allow to quantitatively and objectively 
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merge together results across many independent studies, thus increasing statistical power and validity 
(Wager, Lindquist, Nichols, Kober, & Van Snellenberg, 2009). The meta-analysis presented in this thesis 
was based on 1767 PD patients for the MRI part and 295 for the FDG-PET one. We showed that FDG-PET
is superior in comparison to structural MRI for the identification of PD. Notably, the analysis of Project III 
and Project IV led to similar results concerning the neural correlates of PD patients characterized by 
cognitive deficits. Indeed, the presence of cognitive impairment was in both studies associated with
functional impairment in non-motor regions, i.e. parietal associative cortex and precuneus. In addition, both 
the meta-analytical approach and the comparison between PD with and without MCI showed that the T1-
weighted structural data do not di
Overall, the results of the present work support the use of multimodal neuroimaging as a useful tool to gain 
a better understanding of treatment-related changes and clinical features in PD patients. Further research 
will be needed to translate these finding into clinical applications.
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4. Additional co-authored research 
As extensively introduced in the previous sections and in Project III, cognitive impairments are common in
PD, where deficits in executive functions and attention are predominant. Additionally, memory deficits 
have often been
clear if memory deficits in PD arise from a pure hippocampal dysfunction (similar to that observed in 
by the pervasive failure in attention and executive functions. In the 
following project, we addressed this question combining extensive memory testing and resting-state 
functional MRI to define the functional connectivity of the hippocampus.
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Due to copyright, the paper “Memory impairment in Parkinson’s disease: The retrieval versus associative 
deficit hypothesis revisited and reconciled” authored by Bezdicek, O., Ballarini, T., Buschke, H., Růžička, 
F., Roth, J., Albrecht, F., Růžička, E., Mueller, K., Schroeter, M. L., & Jech, R. published in 
Neuropsychology, 33(3), 391 in 2019 is available online at the publisher’s website: 
https://doi.org/10.1037/neu0000503 and on PubMed with PMID: 30816784 
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Neurodegenerative diseases affect millions of people around the world and, given the progressive aging of 
the population, their deleterious impact is projected to increase in the next future (Dorsey et al., 2007).
, well known because of its typical motor symptoms such as tremor, rigidity, and 
bradykinesia, is the second most co
Disease (de Lau & Breteler, 2006). Despite the fact that the first description of PD dates back to 1817
(Obeso et al., 2017), there is to date no cure to stop or revert the neurodegenerative process. Nevertheless,
the scientific research made significant steps forward, leading to a detailed description of PD 
neuropathology, to effective symptomatic treatments and to a better clinical characterization of the patients.
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Indeed, it is now well established that the core neuropathological hallmarks of PD are alpha-synuclein 
aggregates (Spillantini et al., 1997). These are the main components of the so-called Lewy bodies that are 
found in one of the core nuclei of the dopaminergic system, the substantia nigra pars compacta, and later 
on in the rest of the brain following a clear pattern (Braak et al., 2003). Given that PD neuropathology 
strongly reduces normal nigro-striatal dopaminergic transmission (Cheng et al., 2010), the most common 
treatment for PD is based on dopaminergic therapy (LeWitt, 2008). Using either levodopa a dopamine 
precursor or dopamine agonists, the dopamine levels are temporarily restored, allowing the patients to 
regain control over their movements. In addition, the close clinical observation of PD patients led to the 
conclusion that PD is not only a motor disease, but is characterized by a multitude of non-motor symptoms, 
such as cognitive deficits, anosmia, gastrointestinal problems and sleep disturbances (Chaudhuri et al., 
2006; Schapira et al., 2017).
The results of the scientific endeavor of the last decades led to a better understanding and management of 
PD, but also to new compelling questions. In particular, individual patients present differences in response 
to pharmacological therapy and in clinical presentation, but the sources of this heterogeneity are still 
unclear. The goal of the projects collected in this thesis was to tackle these two issues, merging magnetic 
resonance imaging (MRI) techniques and clinical data. In particular, we aimed to identify novel in vivo
MRI-based biomarkers for the response to dopaminergic therapy and for cognitive deficits in PD. Here we 
focused on the study of brain structural changes, i.e. atrophy, and of brain functional networks at rest. 
Indeed, it has been recently proposed that PD and other neurodegenerative diseases can be described as 
disconnection syndromes closely related to histopathol
(Warren et al., 2012; Warren et al., 2013).
Concerning the treatment of PD, dopaminergic therapy is very effective at the beginning of the treatment, 
but its efficacy decreases over time and a prolonged use often leads to a variety of severe and invalidating
side effects (J. A. Obeso et al., 2000). Moreover, as aforementioned, differences in the individual response 
to the dopaminergic treatment have been reported (Constantinescu et al., 2007).
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In Project I, we investigated how chronic dopaminergic therapy modulates the brain resting-state functional 
connectivity in PD. Patients were under chronic dopaminergic therapy and were studied both in the
medicated (ON) and in the unmedicated (OFF) states and compared to controls. Here we found specific
changes in brain interconnectedness at rest associated with treatment effects. Specifically, when patients 
were OFF medication, they showed elevated functional interconnectedness in cortical sensorimotor areas,
extending to the cerebello-thalamo-cortical pathway and to frontal and parietal brain regions. The ON 
medication state was instead associated with a normalization of this increased connectivity and with lower
connectivity in both motor and non-motor networks. Namely, in the ON compared to OFF state, we 
observed decreased interconnectedness encompassing bilaterally the putamen, precuneus, supplementary 
motor and sensorimotor cortex. These connectivity decreases were evident even in the comparison between 
patients ON medication and healthy controls, especially in the putamen. Overall, we could show that in
chronically treated patients, dopaminergic therapy lowers the connectivity in motor and default mode 
network structures that are aberrantly hyperconnected when the medication is withdrawn. These findings 
provide a further understanding of how brain networks are re-modulated by pharmacological therapy and 
could potentially serve as biomarkers to monitor treatment outcome. We showed, in line with the previous 
literature, that dopaminergic therapy has a strong effect on functional brain architecture that can be studied 
in vivo by means of resting-state functional MRI (Tahmasian et al., 2015).
The aim of Project II
to dopaminergic treatment. Accordingly, we applied machine learning techniques to predict clinical 
response to pharmacological therapy based on structural MRI and demographic/clinical information. We
found that treatment response was independently predicted by both increasing age and by structural brain 
integrity, especially in the left temporoparietal operculum, in the supplementary and primary motor areas 
and in the cerebellum. This study underlines the potential of combining multivariate machine learning 
methods with clinical and brain information. This approach is increasingly popular in the current medical 
research, with the aim to support physicians in performing a more accurate diagnosis and provide the best 
79
possible treatment for each patient. Several small projects, like the one reported here, have shown the 
potential of predictive models and laid the ground for future research. A must for the translation into clinical 
applications will be to increase the sample size and the variability in the data used to create these predictive 
models, in order to allow more reliability and generalizability (Woo et al., 2017).
Concerning the clinical heterogeneity of PD patients, cognitive deficits have been reported in about one-
third of the cases (Litvan et al., 2011) and often lead to overt dementia in the following years (Hoogland et 
al., 2017). To date, there is still no consensus concerning the origin of cognitive impairment in PD.
Project III focused on the study of both structural and resting-state functional MRI for the identification of 
the neural correlates of mild cognitive impairment in PD. Specifically, we found that about 50% of PD 
patients in our sample objectively presented cognitive deficits in different cognitive domains and fulfilled 
the criteria for mild cognitive impairment due to PD (Litvan et al., 2012). The lower cognitive ability was 
associated with more severe functional connectivity impairment. Specifically, both PD patients with mild 
cognitive impairment and those with normal cognition showed functional disconnection in core motor 
regions as compared to healthy age-matched controls. However, only in PD with mild cognitive 
impairment, we observed a characteristic pattern of decreased functional connectivity in the bilateral 
superior parietal lobules and in the precuneus, hubs of the dorsolateral attention network. Notably, only 
brain connectivity differentiated PD with and without mild cognitive impairment, while no differences in 
brain structure were found between the two groups. This confirms that the study of functional brain 
architecture might provide useful information to shed light on the neural correlates of different clinical 
phenotypes. This further insight into the brain abnormalities underlying cognitive impairment in PD could 
be implemented as an additional biomarker for this condition and to inform novel treatment strategies. 
Finally, Project IV also addressed the issue of clinical heterogeneity in PD. Here we run a meta-analysis to 
objectively and quantitatively summarize the recent literature on whole-brain structural MRI and [18F]-
fluorodeoxyglucose-positron emission tomography (FDG-PET) studies comparing PD patients and healthy 
controls. Overall, we included 1767 patients investigated with structural MRI and 295 with FDG-PET. At 
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the first step, we considered, for each imaging modality, all studies together in order to identify a general 
diagnostic imaging biomarker for PD. Here we showed that structural MRI provides heterogeneous results 
across studies and does not offer a specific signature to distinguish PD patients and controls. On the 
contrary, and in agreement with previous findings (Schindlbeck & Eidelberg, 2018), FDG-PET seems to 
be a more sensitive technique for PD diagnosis. At the second step, we stratified the studies according to 
clinical phenotypes, differentiating PD plus cognitive deficits from PD with mainly motor presentation. Of 
note, PD with cognitive deficits was mainly associated with FDG-PET hypometabolism in non-motor 
regions, i.e. in the associative parietal areas bilaterally, thus in line with findings of Project III. 
Overall, the results of these projects support the implementation of multimodal neuroimaging techniques 
to deepen our understanding of both treatment-related changes and clinical heterogeneity in PD. The use of 
similar in vivo neuroimaging biomarkers will be crucial in the next future in both research and clinical 
settings, providing more accurate and earlier diagnosis, a clearer prognosis and more effective 
individualized treatments. Neuroimaging biomarkers have started transforming our understanding and 
management of neurodegenerative diseases and are already implemented in clinical trials and diagnostic 
work-ups for both PD and other neurodegenerative diseases (Politis, 2014). Further research, based on 
larger multicenter samples and leveraging on advanced statistical models, will be crucial to foster this 
promising line of research, and to translate these findings into clinical applications.
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7.1.2. Supplementary Material for Project III
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Figure S1
Abbreviations: DBI: Depression Beck Inventory; FWE: family-wise error; PD-
MCI: Parkinson’s disease with mild cognitive impairment; PD-NC: Parkinson’s
disease with normal cognitio
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Table e-3 Local maxima of ALE analyses in FDG-PET.
Cluster  # Volume (mm3) ALE Value x y z Region
PD-All
1 1424 0.022737322 -14 12 4 Left Caudate Body
2 1416
0.015668042 -42 -56 50 Left Inferior Parietal Lobule
0.015623625 -44 -62 36 Left Middle Temporal Gyrus
3 1336 0.023226662 38 -64 48 Right Precuneus
4 856 0.017095294 16 12 4 Right Caudate Body
PD-Cog
1 1224
0.014935927 -42 -56 50 Left Inferior Parietal Lobule
0.01070755 -42 -66 40 Left Precuneus
2 832 0.01809877 38 -64 48 Right Precuneus
3 680 0.015099958 48 24 -18 Right Inferior Frontal Gyrus
PD-Motor
1 752
0.012473909 -16 14 0 Left Putamen
0.012040857 -14 12 6 Left Caudate Body
Clusters below an anatomical likelihood estimate (ALE) threshold p<0.05 FWE are listed. Coordinates are in MNI 
space. Abbreviations: FWE family wise error, L left, Lat lateralization, MNI Montreal Neurological Institute.
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Table e-4 Local maxima of SDM analyses in FDG-PET.
Cluster  # Voxels SDM-Z x y z p FDR p-value Description
PD-All
1 2217 -4.015 -50 -62 38 ~0 0 Left angular gyrus
2 2070 -3.528 34 -72 38 0.000000060 0.00000036 Right middle occipital gyrus
3 568 -2.894 0 46 20 0.000030518 0.0000916
Left superior medial frontal 
gyrus
4 466 -3.185 -6 14 4 0.000003397 0.0000136 Left caudate nucleus
5 186 -2.804 46 30 -12 0.000058830 0.000141192 Right inferior frontal gyrus
6 45 -2.590 -44 46 -2 0.000255167 0.0004272765 Left middle frontal gyrus
7 43 -2.695 14 12 2 0.000127912 0.000255824
Right anterior thalamic 
projections
8 28 -2.509 46 26 28 0.000424862 0.000432551 Right inferior frontal gyrus
9 27 -2.506 62 -32 -12 0.000432551 0.000432551
Right middle temporal 
gyrus
10 26 -2.508 14 -94 16 0.000430226 0.000432551 Right cuneus cortex
11 25 -2.537 60 -50 -6 0.000357032 0.000432551
Right middle temporal 
gyrus
12 22 -2.574 8 -90 2 0.000284851 0.0004272765 Right calcarine fissure
PD-Cog
1 1452 -5.049 -42 -66 4 ~0 0 Left angular gyrus
2 1306 -3.869 26 -66 52 0.000013649 0.0000265
Right superior parietal 
gyrus
3 466 -3.589 62 -38 -20 0.000024915 0.0000265
Right inferior temporal 
gyrus
4 423 -3.574 -44 36 -14 0.000026524 0.0000265 Left inferior frontal gyrus
5 233 -3.585 46 28 -14 0.000025392 0.0000265 Right inferior frontal gyrus
PD-Motor
1 644 -2.966 -46 -64 36 0.000000358 0.002148 Left angular gyrus
2 591 -2.354 56 24 22 0.000090182 0.000135273 Right inferior frontal gyrus
3 430 -2.439 34 -70 38 0.000045478 0.000111342 Right middle occipital gyrus
4 336 -2.302 -6 14 4 0.000132024 0.0001584288 Left caudate nucleus
5 110 -2.414 6 -64 40 0.000055671 0.000111342 Right precuneus
6 20 -2.166 14 12 2 0.000357211 0.000357211
Right anterior thalamic 
projections
Clusters below an effect-size estimate (SDM) threshold p<0.001 are listed. Coordinates are in MNI space. Abbreviations: FDR 
false discovery rate, MNI Montreal Neurological Institute, PD-all, PD-Cog, PD-Inc, PD-WM, R right.
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Table e-5 Local maxima of ALE analyses in MRI.
Cluster  # Volume (mm3) ALE Value x y z Region
PD-All
1 976 0.0337 -24 -90 24 Left middle occipital gyrus
PD-Cog
1 768 0.0187 -26 -38 -4 Left hippocampus
PD-WM
1 672
0.0120 -18 -36 6 Left thalamus
0.0077 -22 -32 -2 Left thalamus
2 504 0.0108 -20 16 16 Left caudate nucleus
3 496 0.0119 28 -14 0 Right lateral globus pallidus
4 480 0.0116 28 8 12 Right putamen
PD-Inc
1 736 0.0123 18 2 -8 Right medial globus pallidus
Clusters below an anatomical likelihood estimate (ALE) threshold p<0.05 FWE are listed. Coordinates are in MNI space. 




Table e-6 Local maxima of SDM analyses in MRI.
Cluster  # Voxels SDM-Z x y z p FDR p-value Description
PD-All
1 1952 -3.304 -24 -2 -18 ~0 ~0 Left amygdala
2 1804 -3.345 50 2 2 ~0 ~0 Right rolandic operculum
3 33 -2.746 -24 -90 24 0.00025 0.00025 Left superior occipital gyrus
PD-Cog
1 539 -1.624 -22 16 16 0.00018 0.00024
Left anterior thalamic 
projections
2 152 -1.676 26 8 12 0.00010 0.00022 Right striatum
3 86 -1.650 28 -16 0 0.00011 0.00022 Right striatum
4 23 -1.525 -28 -44 0 0.00071 0.00071 Corpus callosum
PD-WM
1 539 -1.624 -22 16 16 0.0002 0.00024
Left anterior thalamic 
projections
2 152 -1.676 26 8 12 0.0001 0.00001 Right striatum
3 86 -1.650 28 -16 0 0.0001 0.00011 Right striatum
4 23 -1.525 -28 -44 0 0.0007 0.00071 Corpus callosum
PD-Inc
1 1262 1.811 26 -46 -38 0.00003 0.00006 Middle cerebellar peduncles
2 335 1.603 26 4 -8 0.00015 0.00015 Right putamen
Clusters below an effect-size estimate (SDM) threshold p<0.001 are listed. Coordinates are in MNI space. Abbreviations: FDR 
false discovery rate, MNI Montreal Neurological Institute, PD- -
patients with cognitive impairment, PD- ients with motor impairment, PD-WM white matter atrophy in 
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Table e-7 Local maxima of ALE analysis in DTI.
Cluster  # Volume (mm3) ALE Value x y z Region
PD-All
1 328 0.0080 -2 14 42 Left cingulate gyrus
2 312 0.0087 10 34 -20 Right anterior cingulate
3 216
0.0076 28 42 14 Right medial frontal gyrus
0.0076 20 46 10 Right medial frontal gyrus
Clusters below an anatomical likelihood estimate (ALE) threshold p<0.001 are listed. Coordinates are in MNI space. 
Abbreviations: MNI Montreal Neurological Institute, PD-
Table e-8 Local maxima of SDM analysis DTI.
Cluster  # Voxels SDM-Z x y z p FDR-p-value Description
PD-All
1 591 -1,832 6 34 -18 0.000001967 0.000003934 Corpus callosum
2 440 -1,437 16 -44 -30 0.000141442 0.000141442
Middle cerebellar 
peduncles
Clusters below an effect-size estimate (SDM) threshold p<0.001 are listed. Coordinates are in MNI space. Abbreviations: 
FDR false discovery rate, MNI Montreal Neurological Institute, PD-
Table e-9 Intensity normalization procedures applied in the included FDG-PET studies.
Study Intensity Normalization Procedures
del Olmo 2006* Global mean normalization
Huang 2013* Global mean normalization
Le Jeune 2010* Global mean normalization
Teune 2010* Global mean normalization
Nagano-Saito 2004* Global mean normalization (on voxels reaching 60% of the highest uptake value)
Pappata`2011 White matter
Yong 2007 White matter
Berti 2012 White matter, but also gray matter and Yakushev normalization
Juh 2003 Cerebellum
Park 2009 Cerebellum
Garcia-Garcia 2012 Normalization to pons activity
Zhang 2016 Not available
Berding 2001 Plasma input functions using the Patlak graphical approach
Edison 2013 Absolute rCMRGlc with arterial input function
* Studies reporting additional hypermetabolism in PD patients compared to controls
rCMRGlc regional Cerebral Metabolic Rate for Gluose
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Cluster  # Volume (mm3) ALE Value x y z Region
PD-All
1 704
3.8905919 40 -64 52 Right superior parietal lobule
3.7190166 39.5 -59.6 50.2 Right precuneus
2 240
3.4316144 -14 12 4
Left nucleus caudatus
3.2905266 -16 10 8
Clusters below an anatomical likelihood estimate (ALE) threshold p<0.001 are listed. Coordinates are in 
MNI space. Abbreviations: MNI Montreal Neurological Institute, PD-
Table e-11 Differences between anatomical likelihood estimation* and seed-based D mapping.
Feature ALE SDM
Version GingerALE 2.3.6 SDM 5.141
Kernel Isotropic Anisotropic
Mask Whole brain Separate for GM and WM
Peak estimation Likelihood Effect size
Finding mean map Statistical sum of 
likelihood values
Weighted average
Resulting maps Likelihood map Effect size map




Sample size and study 
precision
Thresholding FWE, FDR, uncorrected FDR, uncorrected
Further Analysis Contrast analysis Contrast analysis
Extraction of values at regions 
or specific voxels 
Jack-knife analysis
Meta-regression
Abbreviations: ALE anatomical likelihood estimation, FDR false discovery rate, FWE 
familywise error rate, GM gray matter, SDM seed-based D mapping, WM white 
matter. *Note that activation likelihood estimation uses exactly the same algorithms.
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Table e-10 Local maxima of contrast analysis FDG-PET>MRI-VBM in GingerALE
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